These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2007-000290-32 A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Capecitabine in Patients with Locally ... 2010-11-30 bad-data
Completed, but no date 2007-001428-11 Ensayo clínico multicéntrico, abierto, de Fase II con doxorubicina liposomal pegilada (Caelyx®) como tratamiento Primario en pacientes con cáncer de mama y antecedentes de Cardiopatía o con Edad supe... bad-data
Not reported 2011-006083-45 A phase II trial of BKM120 (a PI3K inhibitor) in patients with triple negative metastatic breast cancer 2016-09-11 due-trials
Not reported 2012-000394-23 A Phase II, open-label, single-arm, exploratory pharmacogenomic study of single agent eribulin (HALAVEN®) as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer 2015-10-21 due-trials
Ongoing 2012-001201-24 A prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin (Myocet®) plus paclitaxel, trastuzumab, and pertuzumab in patients with operable HE... not-yet-due
Completed, but no date 2013-001036-22 PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab in Stage I to IIIA HER2-positive breast cancer bad-data
Ongoing 2014-000793-19 A Phase II, Randomized Study of T DM1 versus T DM1 plus short induction with docetaxel in first line treatment for locally advanced or metastatic HER2+ breast cancer. not-yet-due
Ongoing 2014-005006-38 PATRICIA: A Phase II clinical trial of palbociclib and trastuzumab with or without letrozole in postmenopausal pretreated HER2-positive locally advanced or metastatic breast cancer patients not-yet-due
Not reported 2016-003098-17 CORALLEEN: A Phase 2 Clinical Trial of multi-agent Chemotherapy or letrozole plus Ribociclib (LEE001) as neoadjuvant treatment for postmenopausal patients with Luminal B/HER2-negative breast cancer. 2019-07-01 due-trials
Ongoing 2018-003367-58 Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer, who have progressed on or after CDK 4/6 inhibitor t... not-yet-due
Ongoing 2019-000710-11 Targeting EGFR/ERBB2 with Neratinib in Hormone Receptor (HR)-positive/HER2-negative HER2-enriched advanced/metastatic breast cancer (NEREA trial) not-yet-due
Ongoing 2019-002806-28 TARGETING THE PAM50 HER2-ENRICHED PHENOTYPE WITH ENZALUTAMIDE IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER not-yet-due
Ongoing 2019-002991-15 HER2-PREDICT: Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos Ds8201-A-U301 y Ds8201-A-U302 not-yet-due